WASHINGTON--()--2011 BIO International Convention, the largest global event for the biotechnology industry, takes place June 27, 2011 through June 30, 2011 at the Walter E. Washington Convention Center in Washington DC. Exhibitor profiles are listed below.
Business Wire is the official news wire and online press kit service for BIO 2011. Breaking news releases and exhibitor press kits are available at TradeshowNews.com, Business Wire's trade show, conference, and event news resource.
| Company: | Ash Stevens | |
| Booth: | 1817 | |
| Web: | www.ashstevens.com | |
| Ash Stevens, Inc. (ASI) is a full service Contract Pharmaceutical Manufacturer offering comprehensive small-molecule drug substance development and cGMP manufacturing services. ASI has extensive experience developing and manufacturing Active Pharmaceutical Ingredients (APIs). To date, ASI has received eleven FDA manufacturing approvals for innovator APIs, including three Fast Track manufacturing approvals for the active ingredients in the oncology drugs Velcade®, Vidaza®, and Clolar®. Services offered by Ash Stevens include: process development and scale-up; cGMP manufacturing; the development and cGMP manufacture of highly potent APIs using barrier-isolation technology; comprehensive analytical capabilities; and regulatory support for all phases of drug development and manufacturing. | ||
| Company: | Development Center for Biotechnology | |
| Booth: | 4413 | |
| Web: | www.dcb.org.tw | |
| The Development Center for Biotechnology (DCB) of Taiwan is a nonprofit organization founded in 1984 with the objective to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and training talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies. | ||
| Company: | Elan Drug Technologies | |
| Booth: | Partner Suite A129 | |
| Ticker Symbol & Exchange: | NYSE:ELN | |
| Web: | www.elandrugtechnologies.com | |
| Elan Drug Technologies is a global business that provides product development and manufacturing services to the pharmaceutical market. With over 40 years in the service business, we have proven expertise in drug product development, process design and process improvements. Building on our drug delivery and process development expertise, we provide drug product optimization, scale-up and manufacturing services in solid oral dosage forms. We offer our clients unrivalled drug delivery expertise with a suite of commercially launched, proprietary, technology-driven solutions. Over 30 leading pharmaceutical companies are clients of ours, the majority of which are long term strategic partners. For more information see www.elandrugtechnologies.com | ||
| Company: | EStimME | |
| Booth: | 3737 - Hall A | |
| Web: | www.EStimME.com | |
| EStimME is a clinical-phase, medical device start-up company developing a miniaturized implantable system for the treatment of Tinnitus via electrical stimulation of the auditory (cochlear) nerve. | ||
| Tinnitus is the perception of sound, like “ringing in the ears”, in the absence of a physical source. Severe Tinnitus is a large, unmet clinical need affecting around 1% of general population (~3 Million people in the US). | ||
| EStimME’s system consists of A tiny neurostimulator, remotely powered and controlled by an external RF unit. | ||
| The implant has a self-expandable stent-like structure enabling easy deployment and an atraumatic implantation through the ear canal. | ||
| Company: | Galileo Analytics | |
| Booth: | 4146 | |
| Web: | www.galileoanalytics.com | |
| Galileo Analytics is a health data analytics company that uses advanced analytics to transform your ability to understand clinical health data. Our powerful analytical and visualization capabilities provide the ability to analyze vast, complex data sets in minutes, cutting weeks and months from data research timelines and providing real-time answers to critical questions. | ||
| Galileo’s tools empower you to quickly conduct analyses that inform the most vital issues confronting biopharmaceutical companies: | ||
| • Inform licensing decisions through a greater understanding of the treatment landscape | ||
| • Increase value and understanding of clinical trial data | ||
| • Fine-tune marketing strategies | ||
| • Improve post-marketing surveillance and health outcomes analysis capabilities. | ||
| Company: | Life Science Tennessee | |
| Booth: | 4737 | |
| Web: | http://www.lifesciencetn.org/ | |
| Leaders from across Tennessee’s diverse life science sector will present the latest developments in Tennessee-based biotechnology, biofuels, biopharma, biologistics and early-stage venture capital initiatives at the Tennessee Pavilion (booth #4737) during this month’s BIO International Convention in Washington, D.C. Pavilion participants include: Cool Springs Life Sciences Center, DDN, Greater Memphis Chamber, Memphis Bioworks Foundation, Oak Ridge National Laboratory and Tennessee Department of Economic and Community Development. This year’s Pavilion will highlight leading voices from Tennessee’s bioscience industry and will feature some of the state’s greatest assets in the life sciences space including leading institutions Vanderbilt University, University of Tennessee Research Foundation, Memphis Bioworks and Oak Ridge National Laboratory. | ||
| Company: | NeuroVive Pharmaceutical | |
| Booth: | 4425 | |
| Ticker Symbol & Exchange: | NVP (Sweden: AktieTorget) | |
| Web: | www.neurovive.com | |
| NeuroVive Pharmaceutical is a Swedish drug development company whose primary mission is to conduct research and develop pharmaceuticals that protect nerve, cardiac and other cells undergoing health-threatening traumas or ischemia. In addition to conducting or supporting clinical trials of NeuroSTAT® for traumatic brain injuries and CicloMulsion™ to protect cardiac tissue during myocardial infarction, NeuroVive is researching and developing variants of cyclophilin-D-inhibiting cyclosporins and new ways of transporting these drugs across the blood–brain barrier to the CNS. NeuroSTAT® is in a Phase II/III (adaptive) clinical study while CicloMulsion™’s efficacy is being examined in a 1000-person Phase III investigator-initiated study. | ||
| Company: | Sandia National Laboratories | |
| Booth: | 1359 | |
| Web: | www.sandia.gov | |
| The Countering Biological Threats Program at Sandia National Laboratories provides the science, technology, and technical policy solutions for confronting the entire lifecycle of a biological threat – from awareness to prevention, preparedness to detection, and response to recovery. Sandia National Laboratories is a multiprogram laboratory operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy’s National Nuclear Security Administration. With main facilities in Albuquerque, N.M., and Livermore, Calif., Sandia has major R&D responsibilities in national security, energy and environmental technologies, and economic competitiveness. | ||
About Business Wire
Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.
Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.
Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 31 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
